WO2005113529A3 - Neue cylopenta[b]benzofuran-derivate und ihre verwendung - Google Patents

Neue cylopenta[b]benzofuran-derivate und ihre verwendung Download PDF

Info

Publication number
WO2005113529A3
WO2005113529A3 PCT/EP2005/005298 EP2005005298W WO2005113529A3 WO 2005113529 A3 WO2005113529 A3 WO 2005113529A3 EP 2005005298 W EP2005005298 W EP 2005005298W WO 2005113529 A3 WO2005113529 A3 WO 2005113529A3
Authority
WO
WIPO (PCT)
Prior art keywords
utilization
novel
cylopenta
benzofuran derivatives
derivatives
Prior art date
Application number
PCT/EP2005/005298
Other languages
English (en)
French (fr)
Other versions
WO2005113529A2 (de
Inventor
Nicole Diedrichs
Thomas Fahrig
Irene Gerlach
Jacques Ragot
Joachim Schuhmacher
Kai Thede
Ervin Horvath
Original Assignee
Bayer Healthcare Ag
Nicole Diedrichs
Thomas Fahrig
Irene Gerlach
Jacques Ragot
Joachim Schuhmacher
Kai Thede
Ervin Horvath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA06013182A priority Critical patent/MXPA06013182A/es
Priority to US11/596,907 priority patent/US8030347B2/en
Priority to EP05747405A priority patent/EP1751127B1/de
Priority to AU2005245104A priority patent/AU2005245104B2/en
Priority to CN2005800241153A priority patent/CN1989122B/zh
Priority to BRPI0510403-3A priority patent/BRPI0510403A/pt
Application filed by Bayer Healthcare Ag, Nicole Diedrichs, Thomas Fahrig, Irene Gerlach, Jacques Ragot, Joachim Schuhmacher, Kai Thede, Ervin Horvath filed Critical Bayer Healthcare Ag
Priority to JP2007517059A priority patent/JP2007538031A/ja
Priority to CA2567404A priority patent/CA2567404C/en
Publication of WO2005113529A2 publication Critical patent/WO2005113529A2/de
Publication of WO2005113529A3 publication Critical patent/WO2005113529A3/de
Priority to IL179257A priority patent/IL179257A/en
Priority to KR1020067024170A priority patent/KR101215164B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

Die vorliegende Anmeldung betrifft neue Cyclopenta[b]benzofuran-Derivate, der formel (I) in welcher R1, R2, R3, R4, R5, R6, R7 und n wie in den Ansprüchen definiert sind, Verfahren zu ihrer Herstellung sowie ihre Verwendung zur Herstellung von Arzneimitteln, insbesondere zur Prophylaxe und/oder Therapie akuter oder chronischer Erkrankungen, die gekennzeichnet sind durch erhöhten zellulären Stress, durch lokale oder systemische Entzündungsprozesse oder durch Hyperproliferation.
PCT/EP2005/005298 2004-05-18 2005-05-14 Neue cylopenta[b]benzofuran-derivate und ihre verwendung WO2005113529A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US11/596,907 US8030347B2 (en) 2004-05-18 2005-05-14 Cylopenta[b]benzofuran derivatives and the utilization thereof
EP05747405A EP1751127B1 (de) 2004-05-18 2005-05-14 Neue cylopenta[b]benzofuran-derivate und ihre verwendung
AU2005245104A AU2005245104B2 (en) 2004-05-18 2005-05-14 Novel cylopenta[b]benzofuran derivatives and the utilization thereof
CN2005800241153A CN1989122B (zh) 2004-05-18 2005-05-14 新型环戊[b]苯并呋喃衍生物及其用途
BRPI0510403-3A BRPI0510403A (pt) 2004-05-18 2005-05-14 derivados de ciclopenta[b]benzofurano e sua aplicação
MXPA06013182A MXPA06013182A (es) 2004-05-18 2005-05-14 Derivados novedosos de ciclopenta[b] benzofurano y uso de los mismos.
JP2007517059A JP2007538031A (ja) 2004-05-18 2005-05-14 新規なシクロペンタ［ｂ］ベンゾフラン誘導体およびその使用
CA2567404A CA2567404C (en) 2004-05-18 2005-05-14 Cyclopenta[b]benzofuran derivatives and the utilization thereof
IL179257A IL179257A (en) 2004-05-18 2006-11-14 Cyclopenta[b]benzofuran derivatives and the utilization thereof
KR1020067024170A KR101215164B1 (ko) 2004-05-18 2006-11-17 신규 시클로펜타〔ｂ〕벤조푸란 유도체 및 이의 용도

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004024504.5 2004-05-18
DE102004024504A DE102004024504A1 (de) 2004-05-18 2004-05-18 Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung

Publications (2)

Publication Number Publication Date
WO2005113529A2 WO2005113529A2 (de) 2005-12-01
WO2005113529A3 true WO2005113529A3 (de) 2006-02-09

Family

ID=35207782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/005298 WO2005113529A2 (de) 2004-05-18 2005-05-14 Neue cylopenta[b]benzofuran-derivate und ihre verwendung

Country Status (14)

Country Link
US (1) US8030347B2 (de)
EP (1) EP1751127B1 (de)
JP (1) JP2007538031A (de)
KR (1) KR101215164B1 (de)
CN (1) CN1989122B (de)
AU (1) AU2005245104B2 (de)
BR (1) BRPI0510403A (de)
CA (1) CA2567404C (de)
DE (1) DE102004024504A1 (de)
IL (1) IL179257A (de)
MX (1) MXPA06013182A (de)
RU (1) RU2415847C9 (de)
WO (1) WO2005113529A2 (de)
ZA (1) ZA200609444B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1693059A1 (de) * 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Verwendung von Rocaglamidederivate als spezifischen NF-AT Inhibitoren für die Behandlung bestimmter entzündlicher Krankheiten
EP2189453A1 (de) * 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglacolderivate als herzschützende Wirkstoffe
EP2457907A1 (de) * 2010-11-16 2012-05-30 Université de Strasbourg Flavaglinderivate als neuroprotektive Wirkstoffe
US20140255432A1 (en) * 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
FI3888658T3 (fi) 2015-11-25 2024-03-22 Effector Therapeutics Inc eIF4A:ta inhiboivia yhdisteitä ja niihin liittyviä menetelmiä
EP3639820A1 (de) * 2018-10-16 2020-04-22 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Flavaglinderivate zur hemmung der kras-onkogen-aktivierung
CN110646616B (zh) * 2019-09-05 2023-05-30 桂林理工大学 一种检测血清中人cTnI的超敏荧光猝灭免疫传感器及检测方法
CN110776486B (zh) * 2019-10-23 2022-05-20 中国药科大学 一种苯并呋喃类小分子p2y14受体抑制剂，及其制备和应用
KR20240055788A (ko) 2021-09-01 2024-04-29 케이에이치알 바이오텍 게엠베하 신규한 ras 억제제
CN116077483A (zh) * 2021-11-05 2023-05-09 上海中医药大学 楝酰胺及其类似物的药物用途
CN115385924B (zh) * 2022-10-06 2023-10-13 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用
WO2024175659A1 (en) 2023-02-23 2024-08-29 KHR Biotec GmbH 3ah-cyclopenta[b]benzofuran-3a-yl as ras inhibitors
WO2024175662A1 (en) 2023-02-23 2024-08-29 KHR Biotec GmbH Flavagline derivatives as ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007579A2 (de) * 1998-08-05 2000-02-17 Bayer Aktiengesellschaft VERWENDUNG VON CYCLOPENTABENZOFURANDERIVATEN ZUR BEKÄMPFUNG VON NF-λB-ABHÄNGIGEN KRANKHEITEN
WO2000008007A2 (de) * 1998-08-05 2000-02-17 Bayer Aktiengesellschaft Cyclopentabenzofuran-derivate und ihre verwendung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19934952A1 (de) * 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
DE10158561A1 (de) * 2001-11-29 2003-06-12 Bayer Ag Neue Verwendung von Cyclopentabenzofuranen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007579A2 (de) * 1998-08-05 2000-02-17 Bayer Aktiengesellschaft VERWENDUNG VON CYCLOPENTABENZOFURANDERIVATEN ZUR BEKÄMPFUNG VON NF-λB-ABHÄNGIGEN KRANKHEITEN
WO2000008007A2 (de) * 1998-08-05 2000-02-17 Bayer Aktiengesellschaft Cyclopentabenzofuran-derivate und ihre verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIEDRICHS, NICOLE ET AL: "A highly efficient synthesis of rocaglaols by a novel .alpha.-arylation of ketones", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY , (9), 1731-1735 CODEN: EJOCFK; ISSN: 1434-193X, 2005, XP002353478 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C

Also Published As

Publication number Publication date
EP1751127A2 (de) 2007-02-14
DE102004024504A1 (de) 2006-02-16
BRPI0510403A (pt) 2007-10-23
RU2415847C9 (ru) 2011-08-10
AU2005245104B2 (en) 2011-07-28
ZA200609444B (en) 2008-01-30
US20090018113A1 (en) 2009-01-15
CN1989122B (zh) 2013-07-24
AU2005245104A1 (en) 2005-12-01
WO2005113529A2 (de) 2005-12-01
IL179257A (en) 2013-02-28
CA2567404C (en) 2014-04-01
MXPA06013182A (es) 2007-02-14
KR101215164B1 (ko) 2012-12-24
RU2006144710A (ru) 2008-06-27
CN1989122A (zh) 2007-06-27
US8030347B2 (en) 2011-10-04
IL179257A0 (en) 2007-03-08
CA2567404A1 (en) 2005-12-01
EP1751127B1 (de) 2012-07-11
JP2007538031A (ja) 2007-12-27
KR20070011522A (ko) 2007-01-24
RU2415847C2 (ru) 2011-04-10

Similar Documents

Publication Publication Date Title
WO2005113529A3 (de) Neue cylopenta[b]benzofuran-derivate und ihre verwendung
WO2005123736A8 (de) Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
SG158848A1 (en) Method for producing annelated piperazin-2-one derivatives and intermediates of said method
WO2006021379A8 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2006021378A8 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
MXPA05009068A (es) Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos.
WO2006008028A8 (de) Neue 6-formyl-tetrahydropteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel, u.a. gegen krebs
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
WO2006018220A8 (de) Verfahren zur herstellung von dihydropteridinonen
WO2006072347A3 (de) Alkinyl-substituierte thiophene
ZA200606177B (en) 3-'4-heterocyclyl-1,2,3,-triazol-1-yl'-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
WO2006120208A8 (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EP1908749A4 (de) Verfahren zur herstellung von isocyanat, danach hergestelltes isocyanat und verwendung von isocyanat
WO2006059149A8 (en) Arylsulfonylnaphthalene derivatives as 5ht2a antagonists
IL179758A (en) Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof and use of the same as medicaments
TW200611904A (en) Aza-bicyclononanes
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
WO2005121078A3 (de) Substituierte cyclopenten-verbindungen
ATE527266T1 (de) Herstellungsverfahren für asenapin und in diesem verfahren verwendete zwischenprodukte
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
WO2008083950A3 (de) Spirocyclische tetronsäure-derivative
WO2006072348A3 (de) Alkinyl-substituierte thiophene
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005747405

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/013182

Country of ref document: MX

Ref document number: 6708/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006/09444

Country of ref document: ZA

Ref document number: 200609444

Country of ref document: ZA

Ref document number: 179257

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2567404

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067024170

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2005245104

Country of ref document: AU

Ref document number: 2007517059

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005245104

Country of ref document: AU

Date of ref document: 20050514

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005245104

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006144710

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580024115.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020067024170

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005747405

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11596907

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0510403

Country of ref document: BR